Global ANXA5 (Annexin A5) Market Research Report (2025–2036)
Western Market Research predicts that the Global ANXA5 Market was valued at USD 185.6 Million in 2025 and is expected to reach USD 368.4 Million by the year 2036, growing at a CAGR of 6.45% globally during the forecast period.
1. Global ANXA5 Market Overview
Annexin A5 (ANXA5) is a cellular protein belonging to the annexin group, primarily utilized as a highly sensitive probe for detecting apoptosis (programmed cell death). Its unique ability to bind to phosphatidylserine in a calcium-dependent manner has made it an indispensable tool in flow cytometry and molecular imaging.
The market is currently transitioning from a purely research-based reagent to a critical component in diagnostic kit manufacturing and drug toxicity screening. This research study integrates data from 2020–2024 to provide a strategic roadmap for 2026–2036, evaluating the technical progress in recombinant protein expression and the increasing clinical interest in ANXA5 for treating antiphospholipid syndrome and cardiovascular pathologies.
2. Impact of COVID-19 on ANXA5 Market
The COVID-19 pandemic significantly influenced the ANXA5 market. During the initial outbreak in 2020, research into the "cytokine storm" and virus-induced tissue damage relied heavily on ANXA5 to quantify cell death in pulmonary and cardiac tissues. While general academic research faced temporary shutdowns, funding for virology and immunology surged, sustaining demand for high-purity ANXA5. Post-pandemic, the market has benefited from an upgraded global laboratory infrastructure and an increased focus on cellular-level diagnostic precision.
3. Global ANXA5 Market Segmentation
By Purity Type:
-
Above 90%: Primarily used for general laboratory assays and educational purposes.
-
Above 95%: Standard grade for high-throughput screening and biopharmaceutical R&D.
-
Above 99%: Ultra-pure grade required for clinical-grade diagnostic development and crystallography.
By Conjugation/Labeling (New Segment):
-
FITC-Labeled ANXA5: The most common form used in green-fluorescence flow cytometry.
-
Biotin-Conjugated ANXA5: Preferred for secondary detection systems.
-
PE/PerCP Labeled ANXA5: Used in multi-color specialized imaging.
-
Unlabeled/Native ANXA5: Utilized for therapeutic research and functional assays.
By Application:
-
Biopharmaceutical Companies: Drug toxicity testing and apoptosis-mediated drug efficacy studies.
-
Hospitals & Diagnostic Centers: Development of specialized kits for autoimmune and coagulation disorders.
-
Bioscience Research Institutions: Fundamental cell biology and oncology research.
-
Contract Research Organizations (CROs): Outsourced clinical trial monitoring.
4. Top Key Players Covered
The market is characterized by specialized life science companies and large-scale biotechnology conglomerates.
-
Thermo Fisher Scientific (USA)
-
Bio-Rad Laboratories (USA)
-
Merck KGaA (Sigma-Aldrich) (Germany)
-
Abcam (UK)
-
R&D Systems (USA)
-
Cell Signaling Technology (USA)
-
Aviva Systems Biology Corporation (USA)
-
Atlas Antibodies (Sweden)
-
Abbexa Ltd (UK)
-
Boster Biological Technology (USA)
-
BioLegend (USA)
-
Genetex (USA)
-
Novus Biologicals (USA)
-
Proteintech Group (USA)
-
Santa Cruz Biotechnology (USA)
-
BD Biosciences (USA)
-
Cayman Chemical (USA)
5. Regional Analysis
-
North America: Holds the largest market share due to the high density of biopharmaceutical headquarters and substantial NIH funding for cancer research.
-
Europe: A major hub for autoimmune research (particularly in Scandinavia and Germany), driving demand for high-purity ANXA5.
-
Asia-Pacific: The fastest-growing region. Increasing investment in biotechnology in China and India, along with an expanding network of CROs, is accelerating market penetration.
-
South America: Developing market focused on academic research in Brazil and Argentina.
-
Middle East & Africa: Growth is centered around clinical research in South Africa and the UAE.
6. Porter’s Five Forces Analysis
-
Threat of New Entrants (Medium): The requirement for high-precision recombinant protein folding and stabilization technologies acts as a barrier to entry.
-
Bargaining Power of Buyers (High): Research labs and biopharma firms have numerous suppliers and can easily switch based on purity levels and conjugation options.
-
Bargaining Power of Suppliers (Low): Raw materials (media and expression vectors) are standardized and widely available.
-
Threat of Substitutes (Medium): Alternatives like TUNEL assays or Caspase assays exist, but ANXA5 remains the "gold standard" for early-stage apoptosis detection.
-
Competitive Rivalry (High): Major players compete aggressively on product sensitivity, shelf-life, and multi-color labeling options.
7. SWOT Analysis
-
Strengths: High biological specificity for Phosphatidylserine; well-established protocols in flow cytometry.
-
Weaknesses: Sensitive to calcium concentrations; high production costs for ultra-pure recombinant versions.
-
Opportunities: Expansion into in-vivo molecular imaging; use of ANXA5 as a targeted drug delivery vehicle.
-
Threats: Fluctuations in academic research grants; emergence of automated live-cell imaging that may require different markers.
8. Trend Analysis
-
Shift to Recombinant Technology: Traditional extraction is being completely replaced by E. coli and Yeast-based recombinant expression for higher consistency.
-
Multiplexing: Using ANXA5 in combination with other markers (like Propidium Iodide) to distinguish between early apoptosis, late apoptosis, and necrosis.
-
Miniaturization: Integration of ANXA5-based assays into "Lab-on-a-Chip" devices for rapid point-of-care cell analysis.
9. Drivers & Challenges
-
Drivers:
-
Rising global prevalence of cancer requiring extensive apoptosis research.
-
Growth in customized cell-therapy (CAR-T) which uses ANXA5 for quality control.
-
Technological advancements in high-resolution flow cytometers.
-
-
Challenges:
-
Stringent quality control requirements for diagnostic-grade proteins.
-
Limited shelf-life of certain conjugated ANXA5 products.
-
10. Value Chain Analysis
-
Genomic Engineering: Development of optimized ANXA5 expression vectors.
-
Fermentation & Expression: Large-scale protein production using bioreactors.
-
Purification: Multi-step chromatography to achieve >99% purity.
-
Conjugation: Chemically linking fluorophores or enzymes to the protein.
-
Quality Assurance: Batch testing via HPLC and Flow Cytometry.
-
Distribution: Specialized cold-chain logistics to maintain protein folding integrity.
11. Quick Recommendations for Stakeholders
-
For Manufacturers: Focus on developing calcium-independent ANXA5 mutants to allow for greater flexibility in various buffer systems.
-
For R&D Departments: Explore the therapeutic potential of ANXA5 in preventing thrombosis in high-risk pregnancies, as this represents a high-value clinical niche.
-
For Investors: Target mid-sized biotech firms that possess proprietary stable-isotope labeling for ANXA5, as these are critical for advanced proteomics.
-
For Distributors: Strengthen cold-chain networks in the Asia-Pacific region to capitalize on the rapid expansion of biotech research in that area.
1. Market Overview of ANXA5
1.1 ANXA5 Market Overview
1.1.1 ANXA5 Product Scope
1.1.2 Market Status and Outlook
1.2 ANXA5 Market Size by Regions: 2015 VS 2021 VS 2026
1.3 ANXA5 Historic Market Size by Regions
1.4 ANXA5 Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact ANXA5 Sales Market by Type
2.1 Global ANXA5 Historic Market Size by Type
2.2 Global ANXA5 Forecasted Market Size by Type
2.3 Above 90%
2.4 Above 95%
2.5 Above 99%
2.6 Others
3. Covid-19 Impact ANXA5 Sales Market by Application
3.1 Global ANXA5 Historic Market Size by Application
3.2 Global ANXA5 Forecasted Market Size by Application
3.3 Biopharmaceutical Companies
3.4 Hospitals
3.5 Bioscience Research Institutions
3.6 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global ANXA5 Production Capacity Market Share by Manufacturers
4.2 Global ANXA5 Revenue Market Share by Manufacturers
4.3 Global ANXA5 Average Price by Manufacturers
5. Company Profiles and Key Figures in ANXA5 Business
5.1 Aviva Systems Biology Corporation(US)
5.1.1 Aviva Systems Biology Corporation(US) Company Profile
5.1.2 Aviva Systems Biology Corporation(US) ANXA5 Product Specification
5.1.3 Aviva Systems Biology Corporation(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.2 Atlas Antibodies(SE)
5.2.1 Atlas Antibodies(SE) Company Profile
5.2.2 Atlas Antibodies(SE) ANXA5 Product Specification
5.2.3 Atlas Antibodies(SE) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.3 Abbexa Ltd(UK)
5.3.1 Abbexa Ltd(UK) Company Profile
5.3.2 Abbexa Ltd(UK) ANXA5 Product Specification
5.3.3 Abbexa Ltd(UK) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.4 Boster Biological Technology(US)
5.4.1 Boster Biological Technology(US) Company Profile
5.4.2 Boster Biological Technology(US) ANXA5 Product Specification
5.4.3 Boster Biological Technology(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.5 BethylLaboratories(US)
5.5.1 BethylLaboratories(US) Company Profile
5.5.2 BethylLaboratories(US) ANXA5 Product Specification
5.5.3 BethylLaboratories(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.6 Biobyt(UK)
5.6.1 Biobyt(UK) Company Profile
5.6.2 Biobyt(UK) ANXA5 Product Specification
5.6.3 Biobyt(UK) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.7 Bio-Rad(US)
5.7.1 Bio-Rad(US) Company Profile
5.7.2 Bio-Rad(US) ANXA5 Product Specification
5.7.3 Bio-Rad(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.8 Epigentek(US)
5.8.1 Epigentek(US) Company Profile
5.8.2 Epigentek(US) ANXA5 Product Specification
5.8.3 Epigentek(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.9 Genetex(US)
5.9.1 Genetex(US) Company Profile
5.9.2 Genetex(US) ANXA5 Product Specification
5.9.3 Genetex(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.10 Lifespan Biosciences(US)
5.10.1 Lifespan Biosciences(US) Company Profile
5.10.2 Lifespan Biosciences(US) ANXA5 Product Specification
5.10.3 Lifespan Biosciences(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.11 Novus Biologicals(US)
5.11.1 Novus Biologicals(US) Company Profile
5.11.2 Novus Biologicals(US) ANXA5 Product Specification
5.11.3 Novus Biologicals(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.12 Proteintech(US)
5.12.1 Proteintech(US) Company Profile
5.12.2 Proteintech(US) ANXA5 Product Specification
5.12.3 Proteintech(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.13 ProSci(US)
5.13.1 ProSci(US) Company Profile
5.13.2 ProSci(US) ANXA5 Product Specification
5.13.3 ProSci(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.14 R&D Systems(US)
5.14.1 R&D Systems(US) Company Profile
5.14.2 R&D Systems(US) ANXA5 Product Specification
5.14.3 R&D Systems(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.15 Rockland(US)
5.15.1 Rockland(US) Company Profile
5.15.2 Rockland(US) ANXA5 Product Specification
5.15.3 Rockland(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.16 Thermo Fisher Scientific(US)
5.16.1 Thermo Fisher Scientific(US) Company Profile
5.16.2 Thermo Fisher Scientific(US) ANXA5 Product Specification
5.16.3 Thermo Fisher Scientific(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
5.17 USBiological(US)
5.17.1 USBiological(US) Company Profile
5.17.2 USBiological(US) ANXA5 Product Specification
5.17.3 USBiological(US) ANXA5 Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America ANXA5 Market Size
6.2 North America ANXA5 Key Players in North America
6.3 North America ANXA5 Market Size by Type
6.4 North America ANXA5 Market Size by Application
7. East Asia
7.1 East Asia ANXA5 Market Size
7.2 East Asia ANXA5 Key Players in North America
7.3 East Asia ANXA5 Market Size by Type
7.4 East Asia ANXA5 Market Size by Application
8. Europe
8.1 Europe ANXA5 Market Size
8.2 Europe ANXA5 Key Players in North America
8.3 Europe ANXA5 Market Size by Type
8.4 Europe ANXA5 Market Size by Application
9. South Asia
9.1 South Asia ANXA5 Market Size
9.2 South Asia ANXA5 Key Players in North America
9.3 South Asia ANXA5 Market Size by Type
9.4 South Asia ANXA5 Market Size by Application
10. Southeast Asia
10.1 Southeast Asia ANXA5 Market Size
10.2 Southeast Asia ANXA5 Key Players in North America
10.3 Southeast Asia ANXA5 Market Size by Type
10.4 Southeast Asia ANXA5 Market Size by Application
11. Middle East
11.1 Middle East ANXA5 Market Size
11.2 Middle East ANXA5 Key Players in North America
11.3 Middle East ANXA5 Market Size by Type
11.4 Middle East ANXA5 Market Size by Application
12. Africa
12.1 Africa ANXA5 Market Size
12.2 Africa ANXA5 Key Players in North America
12.3 Africa ANXA5 Market Size by Type
12.4 Africa ANXA5 Market Size by Application
13. Oceania
13.1 Oceania ANXA5 Market Size
13.2 Oceania ANXA5 Key Players in North America
13.3 Oceania ANXA5 Market Size by Type
13.4 Oceania ANXA5 Market Size by Application
14. South America
14.1 South America ANXA5 Market Size
14.2 South America ANXA5 Key Players in North America
14.3 South America ANXA5 Market Size by Type
14.4 South America ANXA5 Market Size by Application
15. Rest of the World
15.1 Rest of the World ANXA5 Market Size
15.2 Rest of the World ANXA5 Key Players in North America
15.3 Rest of the World ANXA5 Market Size by Type
15.4 Rest of the World ANXA5 Market Size by Application
16 ANXA5 Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Global ANXA5 Market Segmentation
By Purity Type:
-
Above 90%: Primarily used for general laboratory assays and educational purposes.
-
Above 95%: Standard grade for high-throughput screening and biopharmaceutical R&D.
-
Above 99%: Ultra-pure grade required for clinical-grade diagnostic development and crystallography.
By Conjugation/Labeling (New Segment):
-
FITC-Labeled ANXA5: The most common form used in green-fluorescence flow cytometry.
-
Biotin-Conjugated ANXA5: Preferred for secondary detection systems.
-
PE/PerCP Labeled ANXA5: Used in multi-color specialized imaging.
-
Unlabeled/Native ANXA5: Utilized for therapeutic research and functional assays.
By Application:
-
Biopharmaceutical Companies: Drug toxicity testing and apoptosis-mediated drug efficacy studies.
-
Hospitals & Diagnostic Centers: Development of specialized kits for autoimmune and coagulation disorders.
-
Bioscience Research Institutions: Fundamental cell biology and oncology research.
-
Contract Research Organizations (CROs): Outsourced clinical trial monitoring.
4. Top Key Players Covered
The market is characterized by specialized life science companies and large-scale biotechnology conglomerates.
-
Thermo Fisher Scientific (USA)
-
Bio-Rad Laboratories (USA)
-
Merck KGaA (Sigma-Aldrich) (Germany)
-
Abcam (UK)
-
R&D Systems (USA)
-
Cell Signaling Technology (USA)
-
Aviva Systems Biology Corporation (USA)
-
Atlas Antibodies (Sweden)
-
Abbexa Ltd (UK)
-
Boster Biological Technology (USA)
-
BioLegend (USA)
-
